PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsFluoropyrimidine
Fluoropyrimidine
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
218 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179——13502521291
CarcinomaD002277—C80.05831216
Liver neoplasmsD008113EFO_1001513C22.013—126
Hepatocellular carcinomaD006528—C22.012—1—3
OncogenesD009857—————1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Stomach neoplasmsD013274EFO_0003897C1683116—758
AdenocarcinomaD000230——42012—437
NeoplasmsD009369—C808143—627
Esophageal neoplasmsD004938—C151147—525
Rectal neoplasmsD012004——373—112
Neoplasm metastasisD009362EFO_0009708—165—111
Pancreatic neoplasmsD010190EFO_0003860C25351—310
Colonic neoplasmsD003110—C18144—310
Esophageal squamous cell carcinomaD000077277——151—17
Squamous cell carcinomaD002294——131—15
Show 5 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gastrointestinal neoplasmsD005770—C26.925——411
Breast neoplasmsD001943EFO_0003869C5026——28
Renal cell carcinomaD002292EFO_0000376—33———4
Non-small-cell lung carcinomaD002289——33———4
Triple negative breast neoplasmsD064726——23———4
CholangiocarcinomaD018281—C22.1—1——34
Lung neoplasmsD008175—C34.9014———4
Urologic neoplasmsD014571—C64-C6832———3
Head and neck neoplasmsD006258——13———3
Disease progressionD018450———3———3
Show 26 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Mucinous adenocarcinomaD002288——1————1
CystadenocarcinomaD003536——1————1
LymphomaD008223—C85.91————1
Large b-cell lymphoma diffuseD016403—C83.31————1
Malignant mesotheliomaD000086002——1————1
Ovarian epithelial carcinomaD000077216——1————1
MesotheliomaD008654—C451————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CardiotoxicityD066126EFO_1001482—————44
Drug-related side effects and adverse reactionsD064420—T88.7————22
Gastrointestinal microbiomeD000069196——————11
HypertensionD006973EFO_0000537I10————11
Gallbladder neoplasmsD005706EFO_0004606C23————11
Pseudomyxoma peritoneiD011553EFO_0007456—————11
Cardiovascular diseasesD002318EFO_0000319I98————11
Patient acceptance of health careD010342——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name—
INN—
Description
—
Classification
Unknown
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL ID—
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID—
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
31 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use